



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

27 November 2019

Imagion Biosystems receives \$300K order for supply of nanoparticles

MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, announced that NewPhase Ltd., an Israeli biotechnology company developing cancer treatments, has placed an order totaling approximately \$300K for the supply of Imagion's proprietary nanoparticles for 2020 to be used in the NewPhase product.

As the Company reported in April of 2019, NewPhase is developing a proprietary cancer therapy based on hyperthermia; the principle of killing cancer cells by heating them. NewPhase's treatment approach incorporates the use of Imagion Biosystems' iron oxide nanoparticles into a nanoparticle matrix that targets cancerous tumours. This therapeutic approach, also known as sub ablative hyperthermia, is intended to kill only cancer cells and be harmless to normal tissue.

"We are very pleased to continue to supply NewPhase with our nanoparticles," said Bob Proulx, Executive Chairman of Imagion. "Partnering with companies that can leverage our core nanoparticle technology for complementary medical applications is a key element of our commercial strategy. It is clear we have significant opportunities to monetise our underlying technology for both the detection and treatment of disease."

The overall cancer therapy market is forecast to grow at CAGR 8.37% through 2024, the target-therapy segment, which includes toxin delivery vehicles, is expected to show a higher CAGR of 9.68% in the forecast period. The development of precision medicines such as cancer treatments that target the tumour and spare healthy tissue is a key driver of market growth and new product opportunities.

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations:

Kyahn Williamson, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61-3-9866-4722